IP Library Granted Patent US 8,697,073
Granted Patent B2
US 8,697,073 · App. 13/390,284 · Granted Apr 15, 2014

Anti-podoplanin antibody, and pharmaceutical composition containing anti-podoplanin antibody

Inventors: Yukinari Kato (Yamagata, JP); Mika Kato (Yamagata, JP); Yasuhiko Nishioka (Tokushima, JP)
Assignee: Fujifilm RI Pharma Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,697,073
App. No.
13/390,284
Granted
Apr 15, 2014
Kind
B2
Abstract

Disclosed are: an anti-podoplanin antibody which has a high binding activity and a high effector activity and has low antigenicity in humans or mice; and others. Specifically disclosed are: a chimeric antibody comprising an anti-podoplanin antibody for which an epitope is a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:1 (excluding rat NZ-1 antibody having a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:2 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:3), and a heavy chain complementarity determining region and a light chain complementary determining region of the anti-podoplanin antibody; and others.

Claims (12)

1. A human chimeric anti-podoplanin antibody for which an epitope is a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:1, comprising the following polypeptides:

a) a heavy chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO:6;

b) a heavy chain CDR2 consisting of the amino acid sequence set forth in SEQ ID NO:7;

c) a heavy chain CDR3 consisting of the amino acid sequence set forth in SEQ ID NO:8;

d) a light chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO:9;

e) a light chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO:10;

f) a light chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO:11.

2. The antibody according to claim 1 , comprising VH and VL regions of rat NZ-1 antibody consisting of the amino acid sequence set forth in SEQ ID NO: 18 and 19, respectively, and the CH1, CL, hinge region, CH2, and CH3 of a human antibody.

3. The antibody according to claim 1 , comprising a human IgG1 subclass.

4. A chimeric anti-podoplanin antibody comprising the aminco acid sequence set forth in SEQ ID NO:23.

5. A chimeric anti-podoplanin antibody comprising the aminco acid sequence set forth in SEQ ID NO:37.

6. A chimeric anti-podoplanin antibody comprising the aminco acid sequence set forth in SEQ ID NO:39.

Assignments (6)
CHANGE OF NAME Recorded Feb 23, 2022
From: ZENOAQ RESOURCE CO., LTD.
To: ZENOGEN PHARMA CO., LTD.
Reel/Frame 059071/0555 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2019
From: KATO (30%), YUKINARI
To: ZENOAQ RESOURCE CO., LTD. (70%)
Reel/Frame 050342/0565 →
CHANGE OF NAME Recorded Mar 25, 2019
From: FUJIFILM RI PHARMA CO., LTD.
To: FUJIFILM TOYAMA CHEMICAL CO., LTD.
Reel/Frame 048683/0019 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2019
From: FUJIFILM TOYAMA CHEMICAL CO., LTD.
To: KATO, YUKINARI
Reel/Frame 048683/0123 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2013
From: KATO, YUKINARI
To: FUJIFILM RI PHARMA CO., LTD.
Reel/Frame 030876/0236 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2012
From: KATO, MIKA; NISHIOKA, YASUHIKO
To: KATO, YUKINARI
Reel/Frame 028463/0239 →
Priority Claims (1)
JP 2009-226143 · Sep 30, 2009 · national
Continuity (1)
Related Publication 20120308571A1 · Dec 6, 2012